No description.| Pulmonary Fibrosis News
Software that uses artificial intelligence to analyze medical imaging tests may help facilitate earlier diagnosis and more accurate monitoring of pulmonary fibrosis in people with underlying lung diseases. Brainomix‘s e-Lung could allow doctors to detect progressive pulmonary fibrosis (PPF), where lung tissue becomes increasingly scarred and leads to irreversible lung damage, according to data the […] The post AI tool helps spot lung scarring to aid PF diagnosis, monitoring appeared first...| Pulmonary Fibrosis News – The Web's Daily Resource for PF News
For the first time in more than 10 years, idiopathic pulmonary fibrosis (IPF) care teams and patients will have a new treatment option following the Oct. 7 approval of Jascayd (nerandomilast) by the U.S. Food and Drug Administration (FDA). When I was diagnosed with IPF in January 2017, the only anti-fibrotic medications available to treat […] The post Jascayd is approved! So when can we start taking the IPF treatment? appeared first on Pulmonary Fibrosis News.| Pulmonary Fibrosis News – The Web's Daily Resource for PF News
When my husband, Donnie, started exhibiting concerning symptoms in early 2021, we initially attributed it to a lack of exercise during the pandemic or possibly long COVID-19. The initial shortness of breath he experienced seemed innocent enough, so he shrugged it off as a reminder that he probably needed to get back to the gym. […] The post The long, bumpy road to a pulmonary fibrosis diagnosis appeared first on Pulmonary Fibrosis News.| Pulmonary Fibrosis News – The Web's Daily Resource for PF News
Long-term treatment with deupirfenidone (LYT-100) is generally well tolerated and may stabilize lung function in people with idiopathic pulmonary fibrosis (IPF), according to new clinical trial data announced by the therapy’s developer, Puretech Health. Puretech has already met with the U.S. Food and Drug Administration to discuss the Phase 2b trial data, and the company […] The post Deupirfenidone may stabilize lung function in IPF: Long-term data appeared first on Pulmonary Fibrosis News.| Pulmonary Fibrosis News – The Web's Daily Resource for PF News
Vaccines are a routine part of the pulmonary fibrosis (PF) journey, regardless of where you are along the path. However, recent changes in vaccine guidance from the U.S. Centers for Disease Control and Prevention (CDC) have caused some confusion. When I was diagnosed with idiopathic pulmonary fibrosis in January 2017 at Inova Fairfax’s Advanced Lung […] The post Navigating vaccine recommendations as a PF patient appeared first on Pulmonary Fibrosis News.| Pulmonary Fibrosis News – The Web's Daily Resource for PF News
The U.S. Food and Drug Administration (FDA) has approved nerandomilast, an oral medication developed by Boehringer Ingelheim, to treat adults with idiopathic pulmonary fibrosis (IPF) — when the lung disease has no known cause. The therapy will be marketed under the brand name Jascayd. According to a press release from the FDA, the decision marks […] The post FDA approves Jascayd as first new IPF treatment in over 10 years appeared first on Pulmonary Fibrosis News.| Pulmonary Fibrosis News – The Web's Daily Resource for PF News
In just over a month, one of the largest gatherings of pulmonary fibrosis (PF) patients, caregivers, and health professionals will take place in Chicago, at the Pulmonary Fibrosis Foundation (PFF) Summit 2025. My idiopathic pulmonary fibrosis (IPF) diagnosis in January 2017 thrust my wife, Susan, and me into a whole new world where we didn’t […] The post The Pulmonary Fibrosis Foundation will celebrate 25 years at summit appeared first on Pulmonary Fibrosis News.| Pulmonary Fibrosis News – The Web's Daily Resource for PF News
The Web's Daily Resource for PF News| Pulmonary Fibrosis News
Treatment with the experimental therapy nerandomilast appears to reduce the risk of death in people with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF), according to a new analysis of clinical trial data presented by the therapy’s developer, Boehringer Ingelheim. “The new pooled data zoom in on nerandomilast’s potential as monotherapy, pairing efficacy with […] The post Nerandomilast appears to reduce risk of death in IPF, PPF: trial data appeared first o...| Pulmonary Fibrosis News – The Web's Daily Resource for PF News
My journey to a diagnosis of idiopathic pulmonary fibrosis (IPF) began in the fall of 2016, when I was 59. It all started with a persistent cough. While the cough was annoying, especially to my wife, Susan, it wasn’t limiting my day-to-day activities. After seeing a radiologist’s report, my primary care physician of more than […] The post My IPF diagnostic journey began with a cough that wouldn’t go away appeared first on Pulmonary Fibrosis News.| Pulmonary Fibrosis News – The Web's Daily Resource for PF News
In 2009, I was at a point in my career in cardiology where I’d helped save many lives. I could spell both “pulmonary” and “fibrosis” because of some early transcription work I’d done, but I didn’t know much about pulmonary fibrosis (PF). I was quickly introduced to it when my late husband, Steve, was diagnosed that […] The post Living fully after my late husband’s pulmonary fibrosis diagnosis appeared first on Pulmonary Fibrosis News.| Pulmonary Fibrosis News – The Web's Daily Resource for PF News
For columnist Sam Kirton, Pulmonary Fibrosis Awareness Month is an opportunity to tell others about his journey.| Pulmonary Fibrosis News
Trevi Therapeutics plans to launch two Phase 2 clinical trials testing Haduvio for chronic cough in people with idiopathic pulmonary fibrosis.| Pulmonary Fibrosis News
Trevi has launched a Phase 2b clinical trial to test Haduvio for the treatment of chronic cough in people with idiopathic pulmonary fibrosis.| Pulmonary Fibrosis News
The FDA application followed trial results that showed NP-120 (ifenprodil) was well tolerated for idiopathic pulmonary fibrosis with cough.| Pulmonary Fibrosis News
Enrollment is now complete in the CORAL clinical trial of nalbuphine ER, to be marketed as Haduvio, for IPF patients with chronic cough.| Pulmonary Fibrosis News
A Phase 2b clinical trial testing Haduvio for IPF cough reached 75% of targeted enrollment but is still recruiting patients in 10 countries.| Pulmonary Fibrosis News
No description.| Pulmonary Fibrosis News
GRI-0621, an experimental oral therapy for IPF, may stabilize lung function, according to an interim analysis of an ongoing trial.| Pulmonary Fibrosis News
Columnist Sam Kirton talks to Scott Staszak, president and CEO of the Pulmonary Fibrosis Foundation, about the need for better research.| Pulmonary Fibrosis News
September is Pulmonary Fibrosis Awareness Month, and advocates are hoping to call attention to the condition and interstitial lung diseases.| Pulmonary Fibrosis News
Columnist Sam Kirton takes readers on his journey from a pulmonary function test to his results from lung biopsies that weren't routine.| Pulmonary Fibrosis News
There are more immune NK T-cells in the lungs of people with idiopathic pulmonary fibrosis than in healthy people, research shows| Pulmonary Fibrosis News
Margarida Maia is a science writer for Pulmonary Fibrosis News with a PhD in biomedical sciences. She covers the latest news and information on a variety of pulmonary fibrosis topics.| Pulmonary Fibrosis News
Columnist Sam Kirton finds that filling the silence is part of living with a chronic condition, especially amid retirement and COVID-19.| Pulmonary Fibrosis News
The inhaled NXP002 achieves significant levels in the lungs and lowers the production of scarring-promoting molecules, a study shows.| Pulmonary Fibrosis News
Nuformix received a notice of allowance from the U.S. Patent Office, and awaits a patent for NXP002, an inhaled form of tranilast for IPF.| Pulmonary Fibrosis News
Inconsistent results of NXP002, a new formulation of tranilast, delayed completion of the package needed for potential clinical trials.| Pulmonary Fibrosis News
Treatment with Nuformix's experimental therapy NXP002 reduced markers of fibrosis in a laboratory model of idiopathic pulmonary fibrosis.| Pulmonary Fibrosis News
Category archive page for News.| Pulmonary Fibrosis News
Vanda Pinto is a science writer for Pulmonary Fibrosis News with a PhD in biomedicine. She covers the latest news and information on a variety of pulmonary fibrosis topics.| Pulmonary Fibrosis News
Researchers in China used machine learning to create diagnostic and prognostic models to aid in identifying idiopathic pulmonary fibrosis.| Pulmonary Fibrosis News
IPF treatment candidate CS014 was safe and well tolerated in volunteers in a Phase 1 trial, and showed early promise for reversing scarring.| Pulmonary Fibrosis News
Taladegib has been granted orphan drug designation in the U.S. and the European Union as a treatment for idiopathic pulmonary fibrosis.| Pulmonary Fibrosis News
Columnist Ann Reynoso explains that she's using Ozempic to manage several health issues, but also to hopefully qualify for a lung transplant.| Pulmonary Fibrosis News
While columnist Sam Kirton's quality of life improved after his lung transplant, the healing journey hasn't been easy, he says.| Pulmonary Fibrosis News
Looking for information about pulmonary rehabilitation for pulmonary fibrosis (PF)? Read about it here.| Pulmonary Fibrosis News
Learn more about the signs, symptoms and complications associated with the debilitating respiratory disease pulmonary fibrosis.| Pulmonary Fibrosis News
Learn more about the tests and examinations used to reach a diagnosis of pulmonary fibrosis, which is characterized by scarring in the lungs.| Pulmonary Fibrosis News
Read about the different factors that can cause pulmonary fibrosis.| Pulmonary Fibrosis News
Pulmonary fibrosis is taxing for patients and family. Palliative care aims to help patients live longer and better lives through treatment and assistance.| Pulmonary Fibrosis News
Learn more about Ofev (nintedanib) for the treatment of idiopathic pulmonary fibrosis (IPF).| Pulmonary Fibrosis News
Read about idiopathic pulmonary fibrosis (IPF) — its risk factors, symptoms, and current ways of treating this interstitial lung disease.| Pulmonary Fibrosis News
Learn about familial pulmonary fibrosis, a rare form of pulmonary fibrosis, including its symptoms, diagnosis, risk factors, and treatment.| Pulmonary Fibrosis News
Esbriet (pirfenidone) is an oral treatment that has been approved by the U.S. Food and Drug Administration for idiopathic pulmonary fibrosis.| Pulmonary Fibrosis News
GRI-0621, an experimental oral therapy for IPF, has so far been tolerated well in an ongoing Phase 2 clinical trial.| Pulmonary Fibrosis News
A Texas researcher received a $219,000 NIH grant to study the potential of a treatment for radiation-induced pulmonary fibrosis.| Pulmonary Fibrosis News
During the dog days of summer, columnist Sam Kirton takes special care to protect himself from medication side effects.| Pulmonary Fibrosis News
In CORAL, 165 IPF patients were given one of three doses of nalbuphine ER to test its ability to reduce cough frequency after six weeks.| Pulmonary Fibrosis News
GRI Bio reached an interim enrollment goal for a clinical trial testing GRI-0621, a therapy targeting natural killer T-cells to treat IPF.| Pulmonary Fibrosis News
An EU committee is recommending that tranilast, the active ingredient in a pulmonary fibrosis drug candidate, be awarded orphan drug status.| Pulmonary Fibrosis News
Category archive page for Columns.| Pulmonary Fibrosis News
Columnist Ann Reynoso says she's struggling to lose weight, but each step forward, no matter how small, is still progress.| Pulmonary Fibrosis News
Pulmonary fibrosis is a disease marked by scarring — or fibrosis — of tissue deep in the lungs, making breathing difficult.| Pulmonary Fibrosis News